AbbVie (ABBV)
(Delayed Data from NYSE)
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $194.88 -0.57 (-0.29%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $194.88 -0.57 (-0.29%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
The Zacks Analyst Blog Highlights: Home Depot, AbbVie, Broadcom, 3M and Morgan Stanley
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Home Depot, AbbVie, Broadcom, 3M and Morgan Stanley
Easy Investing Secrets to an Early Retirement - August 13, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
AbbVie Outperforms Large-Cap Pharma Industry Year to Date
by Zacks Equity Research
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are seeing strong sales uptake.
Top Analyst Reports for Home Depot, AbbVie & Broadcom
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot (HD), AbbVie (ABBV) and Broadcom (AVGO).
Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes
by Kinjel Shah
The Zacks Large-Cap Pharmaceuticals industry ranks in the bottom 26% of more than 250 Zacks industries.
Reata (RETA) Q2 Earnings Top, Omaveloxolone Setback Hurts
by Zacks Equity Research
Reata (RETA) gets FDA recommendation to initiate a second study on omaveloxolone for additional data.
Signs That Your Trading Will Ruin Your Retirement - August 11, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Editas' (EDIT) Earnings Beat in Q2, Revenues Improve Y/Y
by Zacks Equity Research
Editas' (EDIT) both bottom and the top line better estimates for the second quarter of 2020.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - August 10, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus
by Kinjel Shah
Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.
Ironwood (IRWD) Q2 Earnings Beat on Solid Linzess Sales
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the second quarter. COVID-19 impacts enrollment in clinical studies.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Want To Retire Early? Learn the Intelligent Investing Secret - August 05, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
3 Diverse Large-Cap Stocks to Buy Now to Boost Your Long-Term Portfolio
by Benjamin Rains
Investors should consider adding a few large-cap names that are prepared to grow for years to come. These three stocks also pay dividends and provide exposure to three very different and vital industries...
Signs That Your Trading Will Ruin Your Retirement - August 03, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
ImmunoGen (IMGN) Q2 Earnings and Sales Beat, Shares Down
by Zacks Equity Research
ImmunoGen (IMGN) reports encouraging second-quarter results. Top-line data from pivotal study on its lead candidate, mirvetuximab soravtansine, likely to be delayed by six to eight weeks.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - August 03, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
AbbVie's (ABBV) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AbbVie (ABBV) beats on second-quarter 2020 earnings and revenues. Shares up in pre-market trading.
More Earnings, Data Following Big Tech Q2 Blowout: XOM, MRK, CAT & More
by Mark Vickery
Markets finish out a busy week in the heart of Q2 earnings season with plenty of other leaders across a spectrum of industries, plus a few new economic reports.
Earnings & Economic Data Deluge
by Zacks Equity Research
Earnings & Economic Data Deluge
AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 4.46% and 2.99%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for AbbVie (ABBV)
by Zacks Equity Research
AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Amgen (AMGN) Stock Moves Lower Despite Q2 Earnings Beat
by Zacks Equity Research
Amgen (AMGN) beats Q2 estimates for both earnings and sales. It maintains its previously-issued sales guidance while raising the earnings range. Stock dips.
Why the Earnings Surprise Streak Could Continue for AbbVie (ABBV)
by Zacks Equity Research
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.